Company intelligence / Profile preview

Agastra Lab

Philadelphia, Pennsylvania, USA

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Agastra is a pre-clinical stage biotechnology company focused on developing next-generation RNA-based therapies for cardiovascular diseases, specifically heart failure. Co-founded by leading researchers from the University of Pennsylvania, including Dr. Thomas Cappola and Dr. Kiran Musunuru, the company leverages mRNA and potentially circular RNA (circRNA) technology to restore cardiac function. Agastra's approach involves the delivery of therapeutic RNA to the heart to express proteins that can repair or improve the performance of failing heart tissue. The company is part of the growing ecosystem of RNA therapeutics startups emerging from academic research in Philadelphia and is supported by PCI Ventures.

Therapeutic areas: Cardiovascular
Modalities: mRNA-based drugsRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Agastra Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agastra Lab.

Explore the full profile